Engage Therapeutics

[Not Yet Scheduled]
Staccato alprazolam is an investigational drug designed to be used as a single-use, epileptic seizure rescue therapy that combines the Staccato delivery technology, which is currently used in a U.S. Food and Drug Administration (FDA) approved product, with alprazolam, an FDA-approved benzodiazepine. It is a small, easy-to-use, hand-held inhaler device that delivers alprazolam with a single normal breath providing a way for people with epilepsy and their caregivers to terminate an ongoing seizure. Engage Therapeutics has completed enrollment in the Phase 2b randomized StATES Study and topline data will be available in early 2020.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
New Jersey
Company HQ Country:
United States
Year Founded:
2017
Main Therapeutic Focus:
Lead Product in Development:
Staccato Alprazolam
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
1
Speaker
photo
President and CEO
Engage Therapeutics